These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16761329)

  • 61. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C].
    Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405
    [No Abstract]   [Full Text] [Related]  

  • 62. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
    Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
    J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
    Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
    Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M
    Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082
    [TBL] [Abstract][Full Text] [Related]  

  • 65. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
    Moreno A; Bárcena R; García-Garzón S; Muriel A; Quereda C; Moreno L; Mateos ML; Fortún J; Martín-Dávila P; García M; Blesa C; Otón E; Moreno A; Moreno S
    J Hepatol; 2005 Nov; 43(5):783-90. PubMed ID: 16084622
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
    Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
    Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.
    Shudo E; Ribeiro RM; Perelson AS
    J Viral Hepat; 2008 May; 15(5):357-62. PubMed ID: 18380660
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
    Erickson AK; Seiwert S; Gale M
    Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Modelling the kinetics of hepatitis C virus RNA decline over 4 weeks of treatment with pegylated interferon alpha-2b.
    Shudo E; Ribeiro RM; Perelson AS
    J Viral Hepat; 2008 May; 15(5):379-82. PubMed ID: 18266841
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics of pegylated interferons: what is misleading?
    Caliceti P
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.
    Lee YJ; Zhang X; Vazquez E; Shivasabesan G; Young HA; Murphy A; Wang H; Suffredini AF; Siebenlist U; Kottilil S
    J Interferon Cytokine Res; 2014 Jan; 34(1):28-34. PubMed ID: 24171456
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PEG-interferon alpha-2b for acute hepatitis C: a review.
    Palumbo E
    Mini Rev Med Chem; 2007 Aug; 7(8):839-43. PubMed ID: 17692045
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy.
    Kimball P; Elswick RK; Shiffman M
    J Med Virol; 2001 Nov; 65(3):510-6. PubMed ID: 11596086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV.
    Talal AH; Shata MT; Markatou M; Dorante G; Chadburn A; Koch R; Neumann AU; Ribeiro RM; Perelson AS
    J Acquir Immune Defic Syndr; 2004 Feb; 35(2):103-13. PubMed ID: 14722440
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modeling HCV kinetics under therapy using PK and PD information.
    Shudo E; Ribeiro RM; Perelson AS
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):321-32. PubMed ID: 19331594
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.
    Berenguer M; Palau A; Aguilera V; Rayón JM; Juan FS; Prieto M
    Am J Transplant; 2008 Mar; 8(3):679-87. PubMed ID: 18294165
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Host Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.
    Sehgal M; Zeremski M; Talal AH; Khan ZK; Capocasale R; Philip R; Jain P
    J Clin Cell Immunol; 2014 Oct; 5():. PubMed ID: 25705565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.